risedronic acid has been researched along with Multiple Myeloma in 7 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, YS | 1 |
| Park, J | 1 |
| De Schutter, JW | 1 |
| Huang, XF | 1 |
| Berghuis, AM | 1 |
| Sebag, M | 1 |
| Tsantrizos, YS | 1 |
| Zhou, X | 1 |
| Born, EJ | 1 |
| Allen, C | 1 |
| Holstein, SA | 1 |
| Wiemer, DF | 1 |
| Lawson, MA | 1 |
| Coulton, L | 1 |
| Ebetino, FH | 2 |
| Vanderkerken, K | 1 |
| Croucher, PI | 1 |
| Roelofs, AJ | 1 |
| Hulley, PA | 1 |
| Meijer, A | 1 |
| Russell, RG | 1 |
| Shipman, CM | 1 |
| Goa, KL | 1 |
| Balfour, JA | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
2 reviews available for risedronic acid and Multiple Myeloma
| Article | Year |
|---|---|
Risedronate.
Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resor | 1998 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
5 other studies available for risedronic acid and Multiple Myeloma
| Article | Year |
|---|---|
Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
Topics: Aminopyridines; Aniline Compounds; Antineoplastic Agents; Apoptosis; Catalytic Domain; Cell Survival | 2012 |
N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.
Topics: Alkyl and Aryl Transferases; Cell Line, Tumor; Drug Discovery; Humans; Molecular Structure; Multiple | 2015 |
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model | 2008 |
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
Topics: Alkyl and Aryl Transferases; Apoptosis; Bone Density Conservation Agents; DNA Replication; Etidronic | 2006 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |